Publications in collaboration with researchers from Fundación Jiménez Díaz (16)

2025

  1. Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis

    Heart Failure Reviews, Vol. 30, Núm. 3, pp. 575-587

  2. Impact of gender on in-hospital and long-term outcomes after transcatheter aortic valve implantation: an analysis of the Spanish TAVI registry

    Revista Espanola de Cardiologia, Vol. 78, Núm. 4, pp. 338-346

2024

  1. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure, Vol. 26, Núm. 9, pp. 1999-2007

  2. Colchicine in acutely decompensated heart failure: the COLICA trial

    European Heart Journal, Vol. 45, Núm. 45, pp. 4826-4836

2022

  1. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

  2. Outcomes of nonagenarians after transcatheter aortic valve implantation

    REC: Interventional Cardiology, Vol. 3, Núm. 4, pp. 250-257

  3. Pronóstico de pacientes nonagenarios tras implante percutáneo de válvula aórtica

    REC: Interventional Cardiology, Vol. 3, Núm. 4, pp. 250-257

2020

  1. Evolución temporal en el tratamiento transcatéter de la estenosis aórtica: análisis del registro español de TAVI

    REC: Interventional Cardiology, Vol. 2, Núm. 2, pp. 96-105

  2. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

  3. Time trend in transcatheter aortic valve implantation: An analysis of the Spanish TAVI registry

    REC: Interventional Cardiology, Vol. 2, Núm. 2, pp. 98-105

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1016-1025

2018

  1. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 553-564

2009

  1. Pronóstico y manejo de los pacientes con síndrome coronario agudo y enfermedad polivascular

    Revista Espanola de Cardiologia, Vol. 62, Núm. 9, pp. 1012-1021

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734